Gilead Sciences, Inc. GILD presented a series of data at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

The company announced results from two studies evaluating the resistance profile of a once-daily single tablet HIV regimen, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF) in virologically suppressed adults switching from dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) or a boosted protease inhibitor (PI)-based regimen for the treatment of HIV-1.

The results showed high rates of virologic suppression with Biktarvy in treatment-experienced adults, regardless of pre-existing resistance to nucleoside reverse transcriptase inhibitors (NRTIs).

We note that Biktarvy is already approved in the United

Read More At Article Source | Article Attribution